Dihydroxyflavones as potential therapeutic agents against inflammation and renal injury via p38 MAP kinase inhibition: an in silico and experimental study.

Farwa Naqvi, Almas Jabeen, Muhammad Shafiq, Shaheen Faizi, Zaheer Ul-Haq

Abstract read

In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Farwa NaqviDr. Panjwani Center for Molecular Medicine and Drug Research, International Centre for Chemical and Biological Sciences, University of Karachi, Karachi, 75270, Pakistan.

Almas JabeenDr. Panjwani Center for Molecular Medicine and Drug Research, International Centre for Chemical and Biological Sciences, University of Karachi, Karachi, 75270, Pakistan. almas@iccs.edu.

Muhammad ShafiqH.E.J Research Institute of Chemistry, International Centre for Chemical and Biological Sciences, University of Karachi, Karachi, 75270, Pakistan.

Shaheen FaiziH.E.J Research Institute of Chemistry, International Centre for Chemical and Biological Sciences, University of Karachi, Karachi, 75270, Pakistan.

Zaheer Ul-HaqDr. Panjwani Center for Molecular Medicine and Drug Research, International Centre for Chemical and Biological Sciences, University of Karachi, Karachi, 75270, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nephrotoxicity poses a significant clinical challenge, contributing to renal complications and increased mortality, thus necessitating novel therapeutics with superior efficacy and safety. Our study addresses this need by evaluating flavone derivatives as potential modulators of p38-MAPK to tackle both inflammation and renal damage, using cell-based assays, cytotoxicity profiling, molecular docking, and ADME-T profiling. Notably, 3,6-dihydroxyflavone (3,6-DHF) and 3,7-dihydroxyflavone (3,7-DHF) demonstrated a significant reduction in KIM-1 mRNA expression in CCl

Indexed as

Anti-Inflammatory AgentsFlavonesInflammationp38 Mitogen-Activated Protein KinasesProtein Kinase InhibitorsAnimalsChlorocebus aethiopsHumansKidneyMolecular Docking SimulationVero CellsAnti-Inflammatory AgentsFlavonesp38 Mitogen-Activated Protein KinasesProtein Kinase InhibitorsAnti-inflammatoryDihydroxyflavoneKidney injury markerNephrotoxicityp38-MAPK

Identifiers

PMID42189167

DOI10.1007/s00210-026-05491-7

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.